KR970706002A - 남성의 상대적 안드로겐 결핍증 치료를 위한 약제의 제조에 있어서 아로마타제 억제제의 용도(Use of Aromatase Inhibitors in the Preparation of a Drug for Treating a Relative Androgen Deficiency in Men) - Google Patents
남성의 상대적 안드로겐 결핍증 치료를 위한 약제의 제조에 있어서 아로마타제 억제제의 용도(Use of Aromatase Inhibitors in the Preparation of a Drug for Treating a Relative Androgen Deficiency in Men)Info
- Publication number
- KR970706002A KR970706002A KR1019970701850A KR19970701850A KR970706002A KR 970706002 A KR970706002 A KR 970706002A KR 1019970701850 A KR1019970701850 A KR 1019970701850A KR 19970701850 A KR19970701850 A KR 19970701850A KR 970706002 A KR970706002 A KR 970706002A
- Authority
- KR
- South Korea
- Prior art keywords
- preparation
- androgen deficiency
- relative androgen
- medicament
- male
- Prior art date
Links
- 239000003886 aromatase inhibitor Substances 0.000 title claims abstract 5
- 239000003814 drug Substances 0.000 title claims abstract 5
- 206010002261 Androgen deficiency Diseases 0.000 title claims abstract 4
- 229940046844 aromatase inhibitors Drugs 0.000 title claims 2
- 229940079593 drug Drugs 0.000 title 1
- 229940122815 Aromatase inhibitor Drugs 0.000 claims abstract 3
- PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 claims abstract 2
- 229950004810 atamestane Drugs 0.000 claims abstract 2
- 229960004421 formestane Drugs 0.000 claims abstract 2
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims abstract 2
- 229960003881 letrozole Drugs 0.000 claims abstract 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- -1 pentrozole Chemical compound 0.000 abstract 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 abstract 1
- 229940078010 arimidex Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Abstract
본 발명은 남성의 상대적 안드로겐 결핍증을 치료하기 위한 약제의 제조에 있어서 아로마타제 억제제의 용도에 관한 것이다. 선택적 아로마타제 억제제는, 예를들어, 아타메스탄, 포르메스탄, 펜트로졸, 아리미덱스, 파드로졸, CGS 20267 및(또는) 보로졸이 있고, 바람직하게는 본 발명에 따른 약제의 제조를 위해 사용된다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (3)
- 남성의 상대적 안드로겐 결핍증을 치료하기 위한 약제의 제조에 있어서 1종 이상의 아로마타제 억제제의 용도.
- 제1항에 있어서, 선택적 아로마타제 억제제의 용도.
- 제2항에 있어서, 아타메스탄, 포르메스탄, 펜트로졸, 아리미덱스, 파드로졸, CGS 20267 보로졸의 용도.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4435368A DE4435368A1 (de) | 1994-09-22 | 1994-09-22 | Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann |
DEP4435368.5 | 1994-09-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR970706002A true KR970706002A (ko) | 1997-11-03 |
KR100387345B1 KR100387345B1 (ko) | 2003-08-30 |
Family
ID=6529877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019970701850A KR100387345B1 (ko) | 1994-09-22 | 1995-09-22 | 남성의상대적안드로겐결핍증치료를위한약제제조용아로마타제억제제의용도 |
Country Status (21)
Country | Link |
---|---|
US (1) | US5861389A (ko) |
EP (1) | EP0782450B1 (ko) |
JP (1) | JPH10505848A (ko) |
KR (1) | KR100387345B1 (ko) |
CN (1) | CN1104243C (ko) |
AT (1) | ATE241989T1 (ko) |
AU (1) | AU707997B2 (ko) |
BR (1) | BR9509155A (ko) |
CA (1) | CA2200195C (ko) |
CZ (1) | CZ76097A3 (ko) |
DE (2) | DE4435368A1 (ko) |
DK (1) | DK0782450T3 (ko) |
ES (1) | ES2199255T3 (ko) |
FI (1) | FI971207A (ko) |
HU (1) | HUT76981A (ko) |
MX (1) | MX9702170A (ko) |
NO (1) | NO971349L (ko) |
PL (1) | PL182909B1 (ko) |
PT (1) | PT782450E (ko) |
SK (1) | SK36397A3 (ko) |
WO (1) | WO1996009057A1 (ko) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19610645A1 (de) | 1996-03-06 | 1997-09-11 | Schering Ag | Kombination von Dehydroepiandrosteron und Aromatasehemmern und Verwendung dieser Kombination zur Herstellung eines Arzeimittels zur Behandlung eines relativen und absoluten Androgenmangels beim Mann |
US5972921A (en) | 1997-12-12 | 1999-10-26 | Hormos Medical Oy Ltd. | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men |
US7067557B2 (en) * | 2000-05-26 | 2006-06-27 | Harry Fisch | Methods of treating androgen deficiency in men using selective antiestrogens |
US6391920B1 (en) | 2000-05-26 | 2002-05-21 | Harry Fisch | Methods of treating androgen deficiency in men using selective antiestrogens |
US6607755B2 (en) * | 2001-06-21 | 2003-08-19 | Michael Donald Farley | Anti-aromatase pharmaceutical composition for controlling testosterone/estrone ratios |
PL211339B1 (pl) * | 2001-07-09 | 2012-05-31 | Zonagen | Zastosowanie kompozycji do wytwarzania leku do leczenia niedoboru testosteronu u samców ssaków |
US7173064B2 (en) * | 2001-07-09 | 2007-02-06 | Repros Therapeutics Inc. | Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy |
US7737185B2 (en) * | 2001-07-09 | 2010-06-15 | Repros Therapeutics Inc. | Methods and compositions with trans-clomiphene |
CN1617715B (zh) * | 2001-12-06 | 2010-05-12 | Gtx公司 | 用雄激素受体选择性调节剂治疗肌消耗 |
US6586417B1 (en) | 2002-04-22 | 2003-07-01 | Nutrisport Pharmacal, Inc. | Ester and ether derivatives of 4-hydroxy 4-androstene-3,17-dione and a method for the regulation of athletic function in humans |
WO2004064813A1 (en) * | 2003-01-13 | 2004-08-05 | Michael Donald Farley | Improvements in or relating to anti-aromatase composition |
WO2004064814A1 (en) * | 2003-01-13 | 2004-08-05 | Michael Donald Farley | Improvements in or relating to anti-aromatase composition |
US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
BRPI0513129A (pt) * | 2004-07-14 | 2008-04-29 | Repros Therapeutics Inc | método de tratamento de condição selecionada do grupo que consiste em hipertrofia benigna de próstata, cáncer de próstata, trigliceridos elevados, colesterol alto e hipogonadismo |
PL219509B1 (pl) * | 2005-02-04 | 2015-05-29 | Repros Therapeutics Inc | Zastosowanie kompozycji zawierającej trans-klomifen |
RU2413508C2 (ru) * | 2005-03-22 | 2011-03-10 | Репрос Терапьютикс Инк. | Режимы дозирования транс-кломифена |
CA2652783C (en) * | 2006-05-22 | 2015-07-14 | Hormos Medical Ltd. | Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis |
UA96076C2 (en) | 2007-10-16 | 2011-09-26 | Репрос Терапьютикс Инк. | Use of trans-clomiphene |
JPWO2009066712A1 (ja) * | 2007-11-21 | 2011-04-07 | クラシエ製薬株式会社 | アロマターゼ阻害剤 |
US20090215738A1 (en) * | 2008-02-26 | 2009-08-27 | Michael Charles Scally | Prevention and treatment of an increase in cardiovascular risk, adverse cardiovascular events, infertility, and adverse psychological effects after androgen or gnrh analogue intake |
CA2673461C (en) * | 2009-08-07 | 2011-07-26 | Bruce W. Kneller | 5.alpha.-androstane-3,6,17-trione (kneller's trione) and methods of use therefor |
US20090306031A1 (en) * | 2009-08-07 | 2009-12-10 | Kneller Bruce W | 5alpha-ANDROSTANE-3,6,17-TRIONE (KNELLER'S TRIONE) AND METHODS OF USE THEREFOR |
UA113291C2 (xx) | 2011-08-04 | 2017-01-10 | Метаболіти транскломіфену і їх застосування | |
CA2881604C (en) * | 2011-08-09 | 2021-09-14 | Kenneth W. Adams | Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males |
ES2613667T3 (es) * | 2011-09-08 | 2017-05-25 | Mereo Biopharma 2 Limited | Composiciones farmacéuticas que comprenden un inhibidor de aromatasa |
CN102641502A (zh) * | 2012-04-25 | 2012-08-22 | 中国农业大学 | 芳香酶抑制剂的新用途 |
MX2015005160A (es) | 2012-11-02 | 2015-07-17 | Repros Therapeutics Inc | Trans-clomifeno para uso en terapia de cancer. |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4289762A (en) * | 1980-06-27 | 1981-09-15 | Merrell Dow Pharmaceuticals Inc. | 10-(1,2-Propadienyl) steroids as irreversible aromatase inhibitors |
US4322416A (en) * | 1980-06-27 | 1982-03-30 | Merrell Dow Pharmaceuticals Inc. | 10-Alkynyl steroids |
DE3362176D1 (en) * | 1982-07-14 | 1986-03-27 | Akzo Nv | Novel 19-thio-androstane derivatives |
DE3322285A1 (de) * | 1983-06-18 | 1984-12-20 | Schering AG, 1000 Berlin und 4709 Bergkamen | 1-alkyl-androsta-1,4-dien-3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
DE3539244A1 (de) * | 1985-11-01 | 1987-05-07 | Schering Ag | 1-methyl-15(alpha)-alkyl-androsta- 1,4-dien-3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
GB8531745D0 (en) * | 1985-12-24 | 1986-02-05 | Erba Farmitalia | 10beta-alkynyl-4-9(11)-estradiene derivatives |
GB8615092D0 (en) * | 1986-06-20 | 1986-07-23 | Erba Farmitalia | Androst-4-ene-317-diones |
DE3705990A1 (de) * | 1987-02-20 | 1988-09-01 | Schering Ag | 1-methyl-15(alpha)-(1-oxyalkyl)-androsta-1,4-dien- 3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
DE3926365A1 (de) * | 1989-08-04 | 1991-02-07 | Schering Ag | Cycloalkylenazole, verfahren zu deren herstellung, pharmazeutische praeparate, die diese enthalten sowie ihre verwendung zur herstellung von arzneimitteln |
GB9226620D0 (en) * | 1992-12-21 | 1993-02-17 | Fujisawa Pharmaceutical Co | A new compound fr 901537,production thereof and use thereof |
-
1994
- 1994-09-22 DE DE4435368A patent/DE4435368A1/de not_active Withdrawn
-
1995
- 1995-09-22 CA CA002200195A patent/CA2200195C/en not_active Expired - Fee Related
- 1995-09-22 JP JP8510608A patent/JPH10505848A/ja active Pending
- 1995-09-22 MX MX9702170A patent/MX9702170A/es not_active IP Right Cessation
- 1995-09-22 US US08/809,582 patent/US5861389A/en not_active Expired - Fee Related
- 1995-09-22 ES ES95934094T patent/ES2199255T3/es not_active Expired - Lifetime
- 1995-09-22 EP EP95934094A patent/EP0782450B1/de not_active Expired - Lifetime
- 1995-09-22 CZ CZ97760A patent/CZ76097A3/cs unknown
- 1995-09-22 PT PT95934094T patent/PT782450E/pt unknown
- 1995-09-22 SK SK363-97A patent/SK36397A3/sk unknown
- 1995-09-22 BR BR9509155A patent/BR9509155A/pt not_active Application Discontinuation
- 1995-09-22 HU HU9701697A patent/HUT76981A/hu unknown
- 1995-09-22 AT AT95934094T patent/ATE241989T1/de not_active IP Right Cessation
- 1995-09-22 KR KR1019970701850A patent/KR100387345B1/ko not_active IP Right Cessation
- 1995-09-22 AU AU36518/95A patent/AU707997B2/en not_active Ceased
- 1995-09-22 DE DE59510714T patent/DE59510714D1/de not_active Expired - Fee Related
- 1995-09-22 WO PCT/EP1995/003733 patent/WO1996009057A1/de not_active Application Discontinuation
- 1995-09-22 CN CN95195216A patent/CN1104243C/zh not_active Expired - Fee Related
- 1995-09-22 DK DK95934094T patent/DK0782450T3/da active
- 1995-09-22 PL PL95319299A patent/PL182909B1/pl not_active IP Right Cessation
-
1997
- 1997-03-21 FI FI971207A patent/FI971207A/fi not_active IP Right Cessation
- 1997-03-21 NO NO971349A patent/NO971349L/no unknown
Also Published As
Publication number | Publication date |
---|---|
ATE241989T1 (de) | 2003-06-15 |
CN1158570A (zh) | 1997-09-03 |
NO971349D0 (no) | 1997-03-21 |
DK0782450T3 (da) | 2003-08-18 |
DE59510714D1 (de) | 2003-07-10 |
CA2200195C (en) | 2008-04-22 |
ES2199255T3 (es) | 2004-02-16 |
SK36397A3 (en) | 1997-08-06 |
CN1104243C (zh) | 2003-04-02 |
HUT76981A (hu) | 1998-01-28 |
CA2200195A1 (en) | 1996-03-28 |
KR100387345B1 (ko) | 2003-08-30 |
EP0782450A1 (de) | 1997-07-09 |
WO1996009057A1 (de) | 1996-03-28 |
AU3651895A (en) | 1996-04-09 |
PL319299A1 (en) | 1997-08-04 |
AU707997B2 (en) | 1999-07-29 |
FI971207A0 (fi) | 1997-03-21 |
BR9509155A (pt) | 1997-10-14 |
PT782450E (pt) | 2003-09-30 |
NO971349L (no) | 1997-05-16 |
JPH10505848A (ja) | 1998-06-09 |
MX9702170A (es) | 1998-04-30 |
PL182909B1 (pl) | 2002-04-30 |
CZ76097A3 (en) | 1997-07-16 |
FI971207A (fi) | 1997-03-21 |
EP0782450B1 (de) | 2003-06-04 |
US5861389A (en) | 1999-01-19 |
DE4435368A1 (de) | 1996-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR970706002A (ko) | 남성의 상대적 안드로겐 결핍증 치료를 위한 약제의 제조에 있어서 아로마타제 억제제의 용도(Use of Aromatase Inhibitors in the Preparation of a Drug for Treating a Relative Androgen Deficiency in Men) | |
GT199800126A (es) | Terapia de combinacion. | |
ATE204164T1 (de) | Pflaster zur behandlung von nagelmykosen | |
ES2160707T3 (es) | Composiciones que comprenden agentes deteriorantes del adn y p53. | |
TR199901172T2 (xx) | Yeni ikame edilmi� pirazol t�revleri. | |
KR960013371A (ko) | 약학적 혼합물 | |
ATE346039T1 (de) | Sulfonamido-substituierte verbrückte bicycloalkylderivative | |
BR9914977A (pt) | Composição para liberação modificada demulti-partìculas | |
KR970704440A (ko) | 당뇨병 타입 ⅱ의 치료용 약물에의 케토코나졸 및 관련 물질의 용도(use of ketoconazole and related substances in medicaments for treatment of type ⅱ diabetes) | |
FR2856294B1 (fr) | Utilisation cosmetique d'une composition comprenant au moins une oxazoline, a titre de principe actif, comme amincissant et/ou pour prevenir et/ou traiter la cellulite | |
NO953370L (no) | Anvendelse av riluzol ved behandling av neuro-AIDS | |
HUP9802971A1 (hu) | Az MMP-inhibitorok alkalmazása a szemben történő érképződés kezelésére | |
SE9604348D0 (sv) | Användning av hydroxyguanidiner | |
BR0112212A (pt) | Uma combinação de inibidores de fbpase e agentes antidiabéticos úteis para o tratamento de diabetes | |
KR960006915A (ko) | 췌장염의 치료 조성물 | |
BR9707844A (pt) | Combinação de desidroepiandrosterona e inibidores de aromatase e emprego desta combinação para a preparação de um medicamento para o tratamento de uma deficiência de androgênio relativa e absoluta no homem | |
NO20020829L (no) | Ny anvendelse av docetaxel for behandling av hepatoma | |
MX9101958A (es) | Inhibidores de acat de urea de aminosulfonilo | |
KR960013376A (ko) | 철과 디프룩토오스를 함유하는 빈혈치료제 | |
ID26965A (id) | Obat untuk mencegah dan/atau mengobati kanker payudara, yang mengandung inhibitor aromatase steroid | |
TR199600117A2 (tr) | Ikame edilen benzolsülfonilüre ve tiyoüre, bu maddelerin elde edilmesi ve eczanecilikle ilgili maddelerin bu bilesimler ve bu bilesimleri iceren iyilestirici maddelere dayanarak kullanilmasi ile ilgili usul. | |
KR970704442A (ko) | 일시적인 병소 허혈에 의해 유발된 재관류 손상을 치료하기 위한 (S)-아데노실-L-메티오닌(SAMe) 및 그의 생리학상 적합한 염의 용도(Use of (S)-Adenosy-L-Methionine(SAMe) and lts Physiologically Compatible Salts for Treating Reperfusion Damage Triggered by Temporary Focal lschaemia) | |
ES2190581T3 (es) | 2-aminotetralina opticamente activa, procedimiento para su preparacion y composiciones farmaceuticas que la contienen, activa en la prevencion y tratamiento de shock septico. | |
DK1042288T3 (da) | Tripeptidyl-peptidase inhibitorer | |
ATE200026T1 (de) | Behandlung von laminitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20080422 Year of fee payment: 6 |
|
LAPS | Lapse due to unpaid annual fee |